{'fraction_non_alphanumeric': 0.031, 'fraction_numerical': 0.002, 'mean_word_length': 4.923076923076923, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Calusterone treatment of breast cancer.

ABSTRACT To the Editor.— Two statements in the recently published "Therapeutic Grand Rounds on Clusterone" in the treatment of advanced breast cancer cast some doubt on the validity of Dr. Gilbert Gordon's enthusiasm for this nontoxic, weak, androgenic steroid. In reply to the question, "How effective is the agent for the young patient in her third decade who has already had bilateral oophorectomy?" The reply was, "It is in this group that the agent has worked extremely well...." Dr. Gordon also stated that "Also, the compound worked equally well in the unfavorable groups of young women in patients with visceral metastases in the lungs and liver." Data are not presented to support these statements. Moreover, it seemed to me that the better calusterone responders used as case illustrations may have been conditioned by previously ineffective estrogen therapy. A 51% response rate as a primary hormonal agent seems unprecedented, especially if indeed